Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 7 |
Nervous System Diseases | 4 |
Neoplasms | 3 |
Infectious Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Hormone | 3 |
Live biotherapeutic products | 3 |
Small molecule drug | 3 |
Synthetic peptide | 2 |
Fecal microbiota transplantation | 1 |
Target- |
Mechanism Bacteria replacements [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date30 Nov 2022 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date16 Jul 2012 |
Target |
Mechanism GnRHR antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date24 Dec 2008 |
Start Date01 Mar 2021 |
Sponsor / Collaborator |
Start Date30 Jul 2019 |
Sponsor / Collaborator |
Start Date08 Feb 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Menotropins ( FSHR x LHCGR ) | Primary Ovarian Insufficiency More | Approved |
Progesterone ( PR ) | Infertility More | Approved |
Somatropin(Ferring Bv) ( GHR ) | Growth Disorders More | Approved |
Fecal microbiota, live-jslm(University of Alberta) | Clostridioides difficile infection recurrence More | Approved |
Corticorelin Ovine Triflutate | Cushing Syndrome More | Approved |